Authors

Latest:

Patient Selection and Sequencing of NSCLC ADCs

The panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.

Timothy J. Pluard, MD

Latest:

Looking Towards The Future of HR+/HER2- Breast Cancer

The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.

Michael Cecchini, MD

Latest:

Dr Cecchini on Etrumadenant-Based Combinations in Previously Treated mCRC

Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.

Jason Zhu, MD

Latest:

Dr. Zhu on Treatment Strategies for Node-Positive Prostate Cancer

Jason Zhu, MD, discusses treatment strategies for patients with node-positive prostate cancer.

Jonathan Spicer, MD, PhD

Latest:

Dr Spicer on Surgical Considerations After Approval of Perioperative Nivolumab in Resectable NSCLC

Jonathan D. Spicer, MD, PhD, FRCS, discusses surgical considerations for patients with for resectable NSCLC after the approval of perioperative nivolumab.

David B. Zhen, MD

Latest:

Immunotherapy's Effect on the Upper GI Cancer Treatment Paradigm

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy has affected the treatment paradigm for upper gastrointestinal cancers.

Joshi Alumkal, MD

Latest:

Dr Alumkal on Standard Treatment Options For Patients With HRD-Altered mCRPC

Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.

Daniel Rotroff, PhD

Latest:

Dr. Rotroff on Biomarkers Associated With the Risk of Peripheral Neuropathy in Breast Cancer

Daniel Rotroff, PhD, discusses the investigation of biomarkers that could help identify patients with breast cancer who are at risk for developing chemotherapy-induced peripheral neuropathy.

LSU LCMC Health Cancer Center

Latest:

LSU Health Professor, Dr. Lucio Miele, Appointed as Director of LSU-LCMC Health Cancer Center

Lucio Miele, MD, PhD of LSU has been appointed as director of the LSU-LCMC Health Cancer Center.

Mostafa Nasr, PhD candidate, Moffitt Cancer Center

Latest:

Nasr on the Need for Preclinical Models of Prostate Cancer Dormancy

Mostafa Nasr, PhD candidate, discusses the development of novel preclinical models of prostate cancer dormancy, and the significance of these outcomes may have on future research in metastatic prostate cancer.

Sarbajit Mukherjee, MD, MS

Latest:

Investigators Seek Simpler Solution to Treatment Resistance in Esophageal Cancer

Although the incidence, location, and histology of esophageal cancer vary globally, patients in the Western World typically develop esophageal cancer in the distal esophagus or at the gastroesophageal junction.

Bassam Sonbol, MD

Latest:

Dr. Sonbol on Navigating Treatment Selection in Gastroesophageal Cancers

Mohamad Bassam Sonbol, MD, discusses key considerations for treatment selection in patients with gastroesophageal junction cancers.

Manali Kamdar, MD

Latest:

Dr Kamdar on the Safety Profile of Liso-Cel Across Patient Subgroups in MCL

Manali Kamdar, MD, discusses common toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

Lakshmi Nayak, MD

Latest:

Dr Nayak on the Investigation of Axi-Cel in CNS Lymphoma

Lakshmi Nayak, MD, discusses the investigation of axi-cel in patients with relapsed/refractory primary and secondary CNS lymphoma.

Lori Muffly, MD

Latest:

Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

The key opinion leaders provide concluding insights and essential recommendations regarding the management of relapsed/refractory acute lymphoblastic leukemia.

Dipenkumar Modi, MD

Latest:

Dr. Modi on the Utility of BTK Inhibitors in CLL

Dipenkumar Modi, MD, discusses the utility of BTK inhibitors in chronic lymphocytic leukemia.

Gabriel Hortobagyi, MD, MACP, FASCO

Latest:

Advances Treating HR+ Metastatic Breast Cancer

Various breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.

Victor Moreno, MD, PhD

Latest:

Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors

Victor Moreno, MD, PhD, discusses insights into the pharmacodynamic activity of CLN-619 for patients with advanced solid tumors.

Deepa Jagadeesh, MD

Latest:

Dr. Jagadeesh on Unmet Needs in Aggressive and Rare Lymphoma Subtypes

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

Peter Kozuch, MD

Latest:

Dr. Kozuch on the Evaluation of ctDNA in the CIRCULATE-US Trial in Resected CRC

Peter Kozuch, MD, discusses the phase 2/3 CIRCULATE-US trial evaluating chemotherapy decisions for patients with resected colorectal cancer based on circulating tumor DNA status.